Provectus Biopharmaceuticals Awarded Patent Extending Protection of the PV-10 Manufacturing Process

Provectus Biopharmaceuticals, Inc. (NYSEMKT:PVCT) announced that it has received a patent from the US Patent and Trademark Office, US Patent No. 9,273,022. The patent extends the scope of protection of the manufacturing process conferred initially by US Patent No. 8,530,675, issued in 2013, to include coverage of the use of an alternative raw material in manufacturing the active ingredient (API) in PV-10.
According to the news:

Provectus believes that this patent, wholly owned by Provectus and conferring coverage to at least 2031, will provide further protection around the proposed commercial process for manufacturing PV-10. Investigational drug product generated using this proprietary technology is being used in all ongoing clinical trials of PV-10, including the pivotal phase 3 trial in melanoma (NCT02288897).

Dr. Eric Wachter, CTO of Provectus, noted:

It is a pleasure to have Cambrex team members as co-inventors on this process patent. Although the scientists and engineers working behind the scenes aren’t always visible to patients or shareholders, these professionals work tirelessly to enable manufacturing the active ingredient in PV-10 on a commercial scale. Chemistry, Manufacturing and Controls (CMC) is a critical part of any investigational new drug (IND) application and subsequent new drug application (NDA), and this aspect of our PV-10 submission is built on a firm foundation, due in no small part to the efforts of the Cambrex team..

Click here to view the full press release.